J&J Units Resolve Spat Over Razadyne-ER Patent

Law360, New York (March 30, 2009, 12:00 AM EDT) -- Three Johnson & Johnson units have resolved a dispute with a trio of generic-drug makers that they accused of infringing a patent covering the Alzheimer’s treatment Razadyne-ER.

According to stipulated dismissals filed late last week and early this week in the U.S. District Court for the District of New Jersey, plaintiffs Janssen LP, Janssen Pharmaceutica NV and Ortho-McNeil Neurologics Inc. agreed to immediately dismiss with prejudice all of their claims.

For their part, defendants KV Pharmaceutical Co., Barr Pharmaceuticals Inc. and Sandoz Inc. agreed to dismiss...
To view the full article, register now.